Pancreatic cancer risk (GLP-1 myth check)
What the FDA labels record as adverse events, each one tied back to the evidence it came from.
What is Pancreatic cancer risk (GLP-1 myth check)?
An early worry from rodent studies showing acinar-cell hyperplasia.
Large human cohorts and the SELECT trial (Lincoff 2023, PMID 37952131) have not shown a pancreatic-cancer signal across years of follow-up. The boxed warning covers thyroid C-cell tumors only; acute pancreatitis is a separate warning in section 5 of the label, and pancreatic cancer is neither. Knowing which warnings are real helps when someone is frightening you toward or away from a purchase.
Related reading: SELECT: When a Weight Drug Became a Cardiac Drug
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Pancreatic cancer risk (GLP-1 myth check) comes up on this site
Connected terms
Other terms under Side effects
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers